Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide tablets, usp (micronized) are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets (micronized) are contraindicated in patients with: 1. known hypersensitivity or allergy to the drug. 2. diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. 3. type i diabetes mellitus. 4. concomitant administration of bosentan.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

atlantic biologicals corp. - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam is contraindicated in patients with

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

insight pharmaceuticals - permethrin (unii: 509f88p9sz) (permethrin - unii:509f88p9sz) - treats head lice

Kanada - Englisch - Health Canada

juno pharmaceuticals corp. - isosorbide-5-mononitrate - tablet (extended-release) - 60mg - isosorbide-5-mononitrate 60mg - nitrates and nitrites

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - prednisone (unii: vb0r961hzt) (prednisone - unii:vb0r961hzt) - prednisone 5 mg - prednisone tablets, usp are indicated in the following conditions: endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus er

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide is indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine 5 mg - amlodipine and benazepril hydrochloride capsules, usp are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), ace inhibitors, including amlodipine and benazepril hydrochloride in patients with diabetes. - amlodipine and benazepril hydrochloride is contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules. - amlodipine and benazepril hydrochloride is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug in 1 ml - paricalcitol injection is an active vitamin d2 analogue indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage 5. paricalcitol injection is contraindicated in patients with evidence of: - hypercalcemia [see warnings and precautions (5.1) ] - vitamin d toxicity [see warnings and precautions (5.1) ] or - hypersensitivity to paricalcitol or any inactive ingredient in this product [see adverse reactions (6.2) ] pregnancy category c paricalcitol has been shown to cause minimal decreases in fetal viability (5%) when administered daily to rabbits at a dose 0.5 times the 0.24 mcg/kg human dose (based on surface area, mg/m2 ) and when administered to rats at a dose 2 times the 0.24 mcg/kg human dose (based on plasma levels of exposure). at the highest dose tested (20 mcg/kg 3 times per week in rats, 13 times the 0.24 mcg/kg human dose based on surface area), there was a significant increase of the mortality of newborn rats at doses that were mate

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

bayer pharmaceuticals corporation - aprotinin bovine (unii: 04xpw8c0fl) (aprotinin bovine - unii:04xpw8c0fl) - 1000000 in 100 ml

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 250 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphylococci skin and ski